Implant Sciences Enters Cooperative R&D Agreement with US DHS's TSL
- QS-B220 further evaluated in Implant Sciences' 2nd CRADA with TSL
Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has signed its second Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Homeland Security's Transportation Security Laboratory (TSL). The Company's first CRADA with the TSL for its QS-B220 desktop explosives trace detector (ETD) began November, 2011. The purpose of the new 12-month CRADA is for the TSL to use the QS-B220, having passed TSA qualification testing, as a gold standard explosives trace detector. Information gathered with the QS-B220 at the TSL will be shared with Implant Sciences and used by the Company to develop next generation trace detection technology.
TSL's core mission is to enhance homeland security, including the research, development and validation of solutions to detect and mitigate the threat of improvised explosive devices (IEDs). TSL, part of the DHS Science and Technology Directorate (S&T), establishes CRADAs as public-private partnerships designed to expeditiously mature and deploy security technologies and to prepare products to achieve Transportation Security Administration (TSA) certification/qualification.
Inorganic Scintillators Market - Competitive Landscape, Global Forecasts & Trends to 2018
TSL conducts research, test and, evaluation at its 110 acre facility located at the FAA William J. Hughes Technical Center, Atlantic City International Airport, New Jersey.
"Our first CRADA with the TSL provided critical input, which was used to improve the performance of our QS-B220 to meet the TSA's standards," stated Implant Sciences' Vice President of Technology, Todd Silvestri. "We believe that the partnership that was developed and the valuable feedback we received from the endeavor helped us tremendously in the QS-B220 attaining the TSA's qualified status for air cargo screening and in passing the QT&E portion of the TSA qualification for checkpoint and checked baggage."
"We believe these studies with the TSL will help to leverage the QS-B220's capabilities and will prove essential to advancing the standards of the trace detection market," stated Implant Sciences' President and CEO Glenn Bolduc. "We are proud to work with the Department of Homeland Security and we look forward to furthering our relationship with the TSL and our technology with this new CRADA."
Source : Implant Sciences Corporation
Sep 22 - 25, 2014 - Austin, United States
Nov 25 - 27, 2014 - Doha, Qatar